By admin 
London-based pharmaceutical giant GSK has announced the discontinuation of its camlipixant development program, a P2X3 receptor antagonist intended for the treatment of refractory chronic cough. The decision comes after the drug yielded mixed results in its pivotal Phase 3 clinical trials, failing to consistently meet its primary endpoints. This marks a significant setback for GSK, which acquired camlipixant through its $2 billion acquisition of Bellus Health in 2023, and represents the third major failure within the P2X3 antagonist class, raising broader questions about the viability of this therapeutic approach for persistent cough.
The announcement, made on July 17, 2026, confirmed that while one of the two late-stage studies showed a statistically significant reduction in 24-hour cough frequency at the higher 50-milligram twice-daily dose, the second study failed to replicate this success. Furthermore, both trials missed crucial key secondary goals, which typically include measures of quality of life and other patient-reported outcomes vital for demonstrating clinical benefit. The lower 25-milligram twice-daily dose also failed to show efficacy in either trial. This inconsistent performance proved insurmountable for GSK, leading to the immediate cessation of further development and a re-evaluation of its strategy in the respiratory therapeutic area.
The Unmet Need in Chronic Cough and the Promise of P2X3 Antagonists
Refractory chronic cough (RCC) is a debilitating condition defined as a persistent cough lasting more than eight weeks, despite adequate investigation and treatment of underlying causes. It affects an estimated 5-10% of the adult population globally, with a significant proportion experiencing severe impairment to their quality of life. Patients often suffer from sleep disruption, urinary incontinence, anxiety, depression, and social isolation due to uncontrollable coughing fits. Current treatment options are limited and often ineffective, primarily relying on off-label use of drugs like gabapentin or pregabalin, which have modest efficacy and notable side effects. This substantial unmet medical need has driven intense pharmaceutical research into novel mechanisms.
The P2X3 receptor, a purinergic receptor found on sensory nerves in the airways, emerged as a promising target. Activation of P2X3 receptors by adenosine triphosphate (ATP) released during inflammation or irritation is believed to play a critical role in mediating cough reflex hypersensitivity. By blocking these receptors, P2X3 antagonists were hypothesized to dampen the hypersensitive cough reflex, thereby reducing cough frequency and severity. This innovative mechanism of action offered hope for a new class of highly effective antitussives.
A Tumultuous Journey: Camlipixant’s Path from Bellus to GSK
Camlipixant’s development journey has been marked by both promise and peril, reflecting the inherent challenges of drug discovery. The drug was initially developed by Bellus Health, a Canadian biopharmaceutical company focused on chronic cough. Its early clinical trajectory was far from smooth.
In 2020, camlipixant (then known as BLU-5937) first encountered a significant hurdle when it failed to meet its primary endpoint in a Phase 2 trial. This initial setback dampened enthusiasm but did not extinguish Bellus’s resolve. The company pressed forward, conducting a second mid-stage study, the CALM-1 (AFLAME) trial, which ultimately delivered more encouraging results. This second Phase 2 study demonstrated a statistically significant reduction in 24-hour cough frequency, particularly with the 50-milligram twice-daily dose. These positive findings reignited interest in camlipixant and, more broadly, in the P2X3 antagonist class.
It was these renewed positive data that caught the attention of GSK. In April 2023, GSK announced its intention to acquire Bellus Health for approximately $2 billion, marking a strategic move to bolster its late-stage pipeline in respiratory diseases. At the time, GSK expressed strong confidence in camlipixant’s potential, citing the compelling data from the second Phase 2 study and the substantial market opportunity in chronic cough. The acquisition was positioned as a key component of GSK’s growth strategy, aimed at delivering new specialty medicines and vaccines. Analysts largely viewed the acquisition positively, acknowledging the high unmet need and the potential for a first-in-class therapy. The deal closed in July 2023, integrating camlipixant into GSK’s extensive research and development portfolio and paving the way for its pivotal Phase 3 program.
Under GSK’s stewardship, camlipixant progressed into the HALO Phase 3 program, comprising two identical studies designed to evaluate its efficacy and safety in patients with refractory chronic cough. The trials aimed to confirm the earlier Phase 2 findings and provide robust data for potential regulatory submission. However, the eagerly anticipated results have now delivered the decisive blow.
Detailed Analysis of the Phase 3 Failures
The HALO program’s mixed outcomes present a complex picture. The fact that the 50-milligram dose achieved statistical significance in one trial but not the other is particularly problematic. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), typically require consistent and reproducible efficacy across multiple well-controlled trials to approve a new drug. A single positive trial, especially when contradicted by a similar study, is rarely sufficient. This inconsistency suggests that the drug’s effect, if present, was not robust enough to be reliably demonstrated.
Moreover, the failure to meet key secondary endpoints further weakens camlipixant’s profile. These secondary endpoints often include patient-reported outcomes (PROs) such as cough-specific quality of life questionnaires (e.g., Leicester Cough Questionnaire), measures of cough severity, sleep disturbance, and overall symptom burden. Even if a drug reduces cough frequency, a lack of improvement in these quality-of-life metrics can raise questions about its clinical meaningfulness and its ability to truly benefit patients in their daily lives. The 25-milligram dose’s complete failure in both trials underscores the dose-response challenges and the difficulty in finding a therapeutic window that balances efficacy with an acceptable safety profile.
Implications for GSK’s Strategy and Financial Outlook
While the discontinuation of camlipixant is undoubtedly disappointing for GSK, particularly given the $2 billion investment in Bellus Health, market analysts have largely downplayed its long-term financial impact on the diversified pharmaceutical giant. Jefferies analyst Michael Leuchten articulated this sentiment in a client note, stating that the failure is "disappointing" but "isn’t a material setback to the GSK equity story." Leuchten’s analysis suggests that GSK’s broader investment thesis is increasingly centered on its robust oncology portfolio, where recent acquisitions and internal assets are perceived to offer "substantially larger and longer-duration value creation opportunities."
This perspective highlights GSK’s strategic pivot under its current leadership. While the Bellus acquisition was initiated during former CEO Emma Walmsley’s tenure, Leuchten notes that current CEO Luke Miels and R&D chief Tony Wood "would have been involved here," suggesting a degree of accountability for the present management team in the acquisition decision and its outcome. However, GSK’s diversified pipeline, encompassing vaccines, infectious diseases, and oncology, provides resilience against the failure of a single asset. The company has made significant strides in oncology with drugs like Jemperli (dostarlimab) and Blenrep (belantamab mafodotin), and continues to invest heavily in these high-growth areas. The camlipixant failure will likely prompt an internal review of GSK’s M&A strategy, particularly concerning late-stage assets in competitive or challenging therapeutic areas.
The Broader Shadow Over P2X3 Antagonists
Camlipixant’s failure is not an isolated incident but rather the latest in a series of setbacks for the P2X3 antagonist class. Before camlipixant, two other prominent P2X3 inhibitors had met similar fates:
- Gefapixant (Merck): Merck’s gefapixant was arguably the furthest along, having received regulatory approval in Japan (under the brand name Lyfnua) in 2022. However, it faced rejection from the FDA in 2022 and the EMA in 2023, both citing concerns over efficacy and safety, particularly taste disturbances (dysgeusia), which were a common side effect. Merck ultimately withdrew its applications in the West.
- Eliapixant (Bayer): Bayer’s eliapixant also failed to demonstrate sufficient efficacy in Phase 2 trials for chronic cough, leading to its discontinuation for this indication in 2021.
The repeated failures across different P2X3 antagonists, from different companies, suggest a potential class effect problem rather than merely a drug-specific issue. While the mechanism of action remains theoretically sound, translating it into a consistently effective and well-tolerated therapy for chronic cough has proven exceedingly difficult. It’s possible that P2X3 receptors play a more nuanced role in cough reflex than initially understood, or that their inhibition leads to off-target effects that compromise their therapeutic utility. This string of failures casts a significant shadow over the entire P2X3 antagonist class, leading many to question its future as a viable therapeutic strategy for chronic cough.
An "Open Field Opportunity" for Competitors: Trevi Therapeutics and Haduvio
The demise of camlipixant, however, has created a significant "open field opportunity" for other companies developing treatments for chronic cough, most notably Trevi Therapeutics. Trevi’s shares experienced a substantial surge, rising as much as 16% in morning trading following GSK’s announcement.
Leerink Partners analyst Roanna Ruiz highlighted this shift, noting that the camlipixant failure effectively clears a major competitor from the landscape. Trevi’s lead product, Haduvio (nalbuphine extended-release), represents an entirely different mechanistic approach to chronic cough. Haduvio is an oral opioid receptor agonist/antagonist that works by modulating the central nervous system pathways involved in cough. It is believed to act as a kappa opioid receptor agonist and a mu opioid receptor antagonist. While opioids are known for their antitussive properties, the unique profile of nalbuphine aims to achieve cough suppression without the typical abuse potential or severe side effects associated with conventional opioids.
Trevi is strategically positioned to capitalize on this cleared field. The company is actively preparing for a Phase 3 trial of Haduvio in patients with chronic cough related to idiopathic pulmonary fibrosis (IPF), a severe lung disease where cough is a prominent and debilitating symptom. Furthermore, Trevi plans to initiate a Phase 2 trial of Haduvio specifically in the refractory chronic cough setting, precisely where camlipixant failed. This direct entry into the most challenging segment of the chronic cough market signals Trevi’s confidence in Haduvio’s unique mechanism and its potential to address the significant unmet need. The competitive landscape for chronic cough is now substantially less crowded, potentially accelerating Haduvio’s path to market if its clinical trials prove successful.
The Enduring Challenge of Drug Development
The camlipixant saga serves as a potent reminder of the inherent risks and complexities involved in pharmaceutical research and development. Even with substantial investment, promising preclinical data, and encouraging early-stage human trials, the path to market is fraught with uncertainty. Late-stage clinical trials, designed to provide definitive evidence of efficacy and safety, often reveal limitations that were not apparent earlier. The high attrition rate for drugs entering Phase 3, particularly in areas with complex pathophysiology like chronic cough, underscores the rigorous standards required for regulatory approval and the challenge of translating scientific hypothesis into tangible patient benefit. For patients suffering from refractory chronic cough, the search for an effective and safe treatment continues, with renewed hope now resting on alternative mechanisms and pipelines.
